ATE553090T1 - Cathepsincysteinproteasehemmer - Google Patents

Cathepsincysteinproteasehemmer

Info

Publication number: ATE553090T1
Authority: AT; Austria
Prior art keywords: protease inhibitors; cathepsincystone; compounds; inhibitors; cathepsins
Prior art date: 2005-07-06

Application number

AT06752874T

Other languages

English (en)

Inventor

Cameron Black

Sheldon Crane

Renata Oballa

Joel Robichaud

Original Assignee

Merck Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-06

Filing date

2006-07-05

Publication date

2012-04-15

2006-07-05 Application filed by Merck Canada Inc filed Critical Merck Canada Inc

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE553090T1 publication Critical patent/ATE553090T1/de

Links

229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
102000005600 Cathepsins Human genes 0.000 abstract 1
108010084457 Cathepsins Proteins 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
-1 but not limited to Substances 0.000 abstract 1
239000002852 cysteine proteinase inhibitor Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000030991 negative regulation of bone resorption Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT06752874T 2005-07-06 2006-07-05 Cathepsincysteinproteasehemmer ATE553090T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69697005P	2005-07-06	2005-07-06
PCT/CA2006/001104 WO2007003056A1 (en)	2005-07-06	2006-07-05	Cathepsin cysteine protease inhibitors

Publications (1)

Publication Number	Publication Date
ATE553090T1 true ATE553090T1 (de)	2012-04-15

Family

ID=37604075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06752874T ATE553090T1 (de)	2005-07-06	2006-07-05	Cathepsincysteinproteasehemmer

Country Status (8)

Country	Link
US (1)	US7928091B2 (de)
EP (1)	EP1902031B1 (de)
JP (1)	JP5122447B2 (de)
CN (2)	CN103172568A (de)
AT (1)	ATE553090T1 (de)
AU (1)	AU2006265735B2 (de)
CA (1)	CA2614070C (de)
WO (1)	WO2007003056A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1855674T1 (sl)	2005-03-02	2014-10-30	Merck Sharp & Dohme Corp.	Sestavek za inhibicijo katepsina k
BR112013015774A2 (pt)	2010-12-01	2018-05-22	Nissan Chemical Industries Ltd	compostos de pirazol tendo efeito terapêutico sobre mieloma múltiplo.
TWI523844B (zh) *	2011-01-26	2016-03-01	賽諾菲公司	經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
KR20140034821A (ko)	2011-05-16	2014-03-20	바이엘 인텔렉쳐 프로퍼티 게엠베하	폐고혈압 및/또는 심부전의 치료 및/또는 예방을 위한 카텝신 k 억제의 용도
US20150023920A1 (en) *	2012-03-29	2015-01-22	Drexel University	Novel compositions and methods for preventing or treating cancer metastasis
US9487483B2 (en)	2012-06-28	2016-11-08	Novartis Ag	Complement pathway modulators and uses thereof
EP3055314B1 (de) *	2013-10-08	2018-09-12	Merck Sharp & Dohme Corp.	Cathepsin-cystein-protease-inhibitoren
WO2015051479A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
WO2015120580A1 (en)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
CN113144178B (zh) *	2014-04-29	2024-10-18	康达医药科技有限公司	采用精氨酸酶i调节免疫系统的方法和组合物
CN106960233A (zh) *	2017-03-20	2017-07-18	广州市度信息技术有限公司	基于rfid的物品位置异常监控方法及装置
CN113332420B (zh) *	2021-06-30	2023-07-28	蚌埠医学院	日本血吸虫半胱氨酸蛋白酶抑制剂在动脉粥样硬化方面的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6525036B2 (en)	2000-01-06	2003-02-25	Merck & Co., Inc.	Compounds and compositions as protease inhibitors
US6462076B2 (en) *	2000-06-14	2002-10-08	Hoffmann-La Roche Inc.	Beta-amino acid nitrile derivatives as cathepsin K inhibitors
US7371747B2 (en) *	2001-11-13	2008-05-13	Merck Frosst Canada & Co.	Cyanoalkylamino derivatives as protease inhibitors
CN1798729A (zh) *	2003-06-02	2006-07-05	霍夫曼-拉罗奇有限公司	苯甲酰胺腈衍生物
WO2005000800A1 (en) *	2003-06-30	2005-01-06	Merck Frosst Canada Ltd.	Cathepsin cysteine protease inhibitors

2006
- 2006-07-05 EP EP06752874A patent/EP1902031B1/de not_active Not-in-force
- 2006-07-05 AU AU2006265735A patent/AU2006265735B2/en not_active Ceased
- 2006-07-05 JP JP2008518583A patent/JP5122447B2/ja not_active Expired - Fee Related
- 2006-07-05 AT AT06752874T patent/ATE553090T1/de active
- 2006-07-05 US US11/988,346 patent/US7928091B2/en active Active
- 2006-07-05 WO PCT/CA2006/001104 patent/WO2007003056A1/en not_active Ceased
- 2006-07-05 CA CA2614070A patent/CA2614070C/en not_active Expired - Fee Related
- 2006-07-05 CN CN201310057161XA patent/CN103172568A/zh active Pending
- 2006-07-05 CN CNA2006800246166A patent/CN101218207A/zh active Pending

Also Published As

Publication number	Publication date
JP5122447B2 (ja)	2013-01-16
WO2007003056A1 (en)	2007-01-11
EP1902031B1 (de)	2012-04-11
CN101218207A (zh)	2008-07-09
CN103172568A (zh)	2013-06-26
EP1902031A1 (de)	2008-03-26
AU2006265735B2 (en)	2011-08-04
EP1902031A4 (de)	2009-09-16
AU2006265735A1 (en)	2007-01-11
CA2614070A1 (en)	2007-01-11
US7928091B2 (en)	2011-04-19
CA2614070C (en)	2014-03-25
JP2009500300A (ja)	2009-01-08
US20090093444A1 (en)	2009-04-09

Publication	Publication Date	Title
ATE395911T1 (de)	2008-06-15	Cathepsin-cystein-protease-hemmer
ATE409482T1 (de)	2008-10-15	Cathepsincystein-proteasehemmer
TW200631576A (en)	2006-09-16	Cathepsin cysteine protease inhibitors
NO20061627L (no)	2006-04-10	Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer
SG151303A1 (en)	2009-04-30	New compounds for the inhibition of angiogenesis and use thereof
ATE553090T1 (de)	2012-04-15	Cathepsincysteinproteasehemmer
NO20075370L (no)	2007-12-19	Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
CY1107342T1 (el)	2012-12-19	Χρηση παραγωγων νιτριλιου ως φαρμακο
WO2005063742A3 (en)	2005-08-18	Amidino compounds as cysteine protease inhibitors
NO20080661L (no)	2008-03-04	Nye cystein-protease-inhibitorer og deres terapeutiske anvendelser
MX2009003563A (es)	2009-04-15	Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
WO2002070517A3 (en)	2003-01-16	Cathepsin cysteine protease inhibitors
MX2007011739A (es)	2008-03-14	Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
TN2009000448A1 (en)	2011-03-31	Use of hdac inhibitors for the treatment of bone destruction
MY139221A (en)	2009-08-28	Cathepsin cysteine protease inhibitors
DOP2005000240A (es)	2006-06-15	Inhibidores de catepsina cisteina proteasas
UA95930C2 (uk)	2011-09-26	Інгібітори цистеїнпротеаз, фармацевтична композиція, яка їх містить, та їх терапевтичне застосування
TH83709A (th)	2007-03-29	สารยับยั้งคาเทปซิน ซิสเตอีน โปรตีเอส